Table 1

Next-generation sequencing studies

AuthorYearnTumor siteStageSampleSequenceReference
Friedlander2016105N/AN/AFFPE46-gene panel 45
Wang201735PrimaryN/AFrozen tissueWhole-genome sequencing 43
Maru201718PrimaryI/II 15 (83.3%)
III/IV 3 (16.7%)
FFPE409-gene panel 49
Elvin2017125Primary (45.6%) and metastatic (54.4%)N/AFFPEFoundationOne 315-gene panel 55
Arildsen201710PrimaryN/AFFPE60-gene panel 54
Itamochi201755PrimaryI/II 33 (60%)
III/IV 22 (40%)
Frozen tissueWhole-genome sequencing 41
Murakami201739PrimaryN/AFrozen tissueWhole-exome sequencing 42
Shibuya201748PrimaryI/II 29 (60.4%)
III/IV 19 (39.6%)
FFPEWhole-exome sequencing 48
Kim201815PrimaryI/II 11 (73.3%)
III/IV 4 (26.7%)
Frozen tissueWhole-exome sequencing 44
Caumanns2018124PrimaryN/AFrozen tissueKinome sequencing
518 kinases, 13 diglyceride kinases, 18 PI3K domain and regulatory component genes, and 48 cancer-related genes
127
Takenaka201968PrimaryI/II 19 (27.9%)
III/IV 49 72.0%)
FFPE103-gene panel 51
  • FFPE, formalin-fixed paraffin-embedded tissue; N/A, not available.